Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation

Vaccine

Volumn 29, Issue 4, 2011, Pages 795-803

  Dolter, Karen E ^a   Evans, Claire F ^a   Ellefsen, Barry ^a   Song, Juwan ^a   Boente Carrera, Mar ^b   Vittorino, Roselle ^b   Rosenberg, Talia J ^b   Hannaman, Drew ^a   Vasan, Sandhya ^b  

^a Ichor Medical Systems Inc   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

DNA vaccine; Electroporation; Integration

Indexed keywords

ADVAX; DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SAFETY; ELECTROPORATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT;

AIDS VACCINES; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ELECTROPORATION; FEMALE; HIV-1; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED BALB C; PLASMIDS; RABBITS; RATS; RATS, WISTAR; VACCINATION; VACCINES, DNA;

EID: 78650568204     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.011     Document Type: Article

References (59)

1. Barré-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220(4599):868-871.
2. Gallo R.C., Salahuddin S.Z., Popovic M., Shearer G.M., Kaplan M., Haynes B.F., et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984, 224(4648):500-503.
3. AIDS Epidemic Update. UNAIDS/WHO. UNAIDS/09.36E/JC1700E; November 2009.
4. Towards universal access: scaling up priority HIV/AIDS Interventions in the health sector. Progress report 2009, WHO/UNAIDS/UNICEF.
5. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.
6. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003, 9:729-735.
7. Goonetilleke N., Moore S., Dally L., Winstone N., Cebere I., Mahmoud A., et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 gag coupled to CD8+ T-cell epitopes. J Virol 2006, 80:4717-4728.
8. Harari A., Bart P.A., Stöhr W., Tapia G., Garcia M., Medjitna-Rais E., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008, 205:63-77.
9. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000, 18:927-974.
10. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu Rev Immunol 1997, 15:617-648.
11. Rosati M., Bergamaschi C., Valentin A., Kulkarni V., Jalah R., Alicea C., et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A 2009 Sep 15, 106(37):15831-15836. [Epub 2009 August 28].
12. Fuller D.H., Rajakumar P.A., Wilson L.A., Trichel A.M., Fuller J.T., Shipley T., et al. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 2002, 76(April (7)):3309-3317.
13. Schalk J.A., Mooi F.R., Berbers G.A., van Aerts L.A., Ovelgonne H., Kimman T.G. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccines 2006, 2(2):45-53.
14. Mulligan M.J., Russell N.D., Celum C., Kahn J., Noonan E., Montefiori D.C., et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses 2006, 22:678-683.
15. Catanzaro A.T., Roederer M., Koup R.A., Bailer R.T., Enama M.E., Nason M.C., et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007, 25:4085-4092.
16. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase I safety and immunogenicity evaluation of a multiclade HIV-1 candidate DNA vaccine. J Infect Dis 2006, 194:1650-1660.
17. Gorse G.J., Baden L.R., Wecker M., Newman M.J., Ferrari G., Weinhold K.J., et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 2008, 26(2):215-223.
18. Jaoko W., Nakwagala F.N., Anzala O., Manyonyi G.O., Birungi J., Nanvubya A., et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008, 26(22):2788-2795.
19. Manoj S., Babiuk L.A., van Drunen Littel-van den Hurk S. Approaches to enhance the efficacy of DNA vaccines. Crit Rev Clin Lab Sci 2004, 41(1):1-39.
20. Drape R.J., Macklin M.D., Barr L.J., Jones S., Haynes J.R., Dean H.J. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006, 24(21):4475-4481.
21. Jones S., Evans K., McElwaine-Johnn H., Sharpe M., Oxford J., Lambkin-Williams R., et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009, 27(18):2506-2512.
22. Luxembourg A., Evans C.F., Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther 2007, 7(11):1647-1664.
23. Otten G., Schaefer M., Doe B., Liu H., Srivastava I., zur Megede J., et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22(19):2489-2493.
24. Luxembourg A., Hannaman D., Ellefsen B., Nakamura G., Bernard R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 2006, 24(21):4490-4493.
25. Livingston B.D., Little S.F., Luxembourg A., Ellefsen B., Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 2010, 28(4):1056-1061.
26. LeBlanc R., Vasquez Y., Hannaman D., Kumar N. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine 2008, 26(2):185-192.
27. Bodles-Brakhop A.M., Draghia-Akli R. DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 2008, 7(7):1085-1101.
28. Best S.R., Peng S., Juang C.M., Hung C.F., Hannaman D., Saunders J.R., et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 2009, 27(40):5450-5459.
29. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nat Rev Genet 2008, 9(10):776-788.
30. van Drunen Littel-van den Hurk S., Hannaman D. Electroporation for DNA immunization: clinical application. Expert Rev Vaccines 2010, 9(5):503-517.
31. Huang Y., Chen Z., Zhang W., Gurner D., Song Y., Gardiner D.F., et al. Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant. J Acquir Immune Defic Syndr 2008, 47(4):403-411.
32. Vasan S., Schlesinger S.J., Huang Y., Hurley A., Lombardo A., Chen Z., et al. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One 2010, 5(1). e8617, 1-7.
33. Bregman C.L., Adler R.R., Morton D.G., Regan K.S., Yano B.L. Society of toxicologic pathology. Recommended tissue list for histopathologic examination in repeat-dose toxicity and carcinogenicity studies: a proposal of the Society of Toxicologic Pathology (STP). Toxicol Pathol 2003, 31(2):252-253.
34. Ledwith B.J., Manam S., Troilo P.J., Barnum A.B., Pauley C.J., Griffiths T.G., et al. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 2000, 43(4-6):258-272.
35. Guidance for industry: considerations for plasmid DNA vaccines for infectious disease indications November 2007, Food and Drug Administration Center for Biologics Evaluation and Research.
36. Cristillo A.D., Weiss D., Hudacik L., Restrepo S., Galmin L., Suschak J., et al. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem Biophys Res Commun 2008, 366(1):29-35.
37. Hirao L.A., Wu L., Khan A.S., Hokey D.A., Yan J., Dai A., et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008, 26(25):3112-3120.
38. Liu J., Kjeken R., Mathiesen I., Barouch D.H. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 2008, 82(11):5643-5649.
39. Selby M., Goldbeck C., Pertile T., Walsh R., Ulmer J. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 2000, 83:147-152.
40. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000, 164:4635-4640.
41. Simon A.J., Casimiro D.R., Finnefrock A.C., Davies M.E., Tang A., Chen M., et al. Enhanced in vivo transgene expression and immunogenicity from plasmid vectors following electrostimulation in rodents and primates. Vaccine 2008, 26:5202-5209.
42. Otten G.R., Schaefer M., Doe B., Liu H., Megede J.Z., Donnelly J., et al. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 2006, 24:4503-4509.
43. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81(10):5257-5269.
44. McCormack S., Stöhr W., Barber T., Bart P.A., Harari A., Moog C., et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26(25):3162-3174.
45. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells. Blood 2006, 107:4781-4789.
46. Luxembourg A., Hannaman D., Nolan E., Ellefsen B., Nakamura G., Chau L., et al. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 2008, 26(40):5216-5222.
47. Laddy D.J., Yan J., Kutzler M., Kobasa D., Kobinger G.P., Khan A.S., et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 2008, 3(6):e2517.
48. van Drunen Littel-van den Hurk S., Luxembourg A., Ellefsen B., Wilson D., Ubach A., Hannaman D., et al. Electroporation-based DNA transfer enhances gene expression and immune responses to DNA vaccines in cattle. Vaccine 2008, 26(October (43)):5503-5509.
49. Babiuk S., Baca-Estrada M.E., Foldvari M., Middleton D.M., Rabussay D., Widera G., et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol 2004, 110(1):1-10.
50. Aihara H., Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998, 16(9):867-870.
51. Dupuis M., Denis-Mize K., Woo C., Goldbeck C., Selby M.J., Chen M., et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol 2000, 165(5):2850-2858.
52. Wang Z., Troilo P.J., Wang X., Griffiths T.G., Pacchione S.J., Barnum A.B., et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 2004, 11:711-721.
53. Davis H.L., Millan C.L., Watkins S.C. Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA. Gene Ther 1997, 4(3):181-188.
54. Wells K.E., Maule J., Kingston R., Foster K., McMahon J., Damien E., et al. Immune responses, not promoter inactivation, are responsible for decreased long-term expression following plasmid gene transfer into skeletal muscle. FEBS Lett 1997, 407(2):164-168.
55. Sheets R.L., Stein J., Manetz T.S., Duffy C., Nason M., Andrews C., et al. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 2006, 91(2):610-619.
56. Martin T., Parker S.E., Hedstrom R., Le T., Hoffman S.L., Norman J., et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 1999, 10(March (5)):759-768.
57. Vilalta A., Mahajan R.K., Hartikka J., Leamy V., Martin T., Rusalov D., et al. II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Hum Gene Ther 2005, 16(10):1151-1156.
58. Vilalta A., Mahajan R.K., Hartikka J., Rusalov D., Martin T., Bozoukova V., et al. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum Gene Ther 2005, 16(10):1143-1150.
59. Vasan S., Hurley A., Schlesinger S.J., Hannaman D., Gardiner D.F., Dugin D.P., et al. OA05-01. In vivo electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers. Retrovirology 2009, 6(Suppl. 3):O31.